Bain Capital Life Sciences Investors’s Kailera Therapeutics KLRA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio KLRA Stock Details KLRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$498M	Buy	+22,583,268	New	+$496M	29.58%	1

Other funds holding KLRA

BCI

Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bain Capital Life Sciences Investors's KLRA Position: Q2 2026 in Review

Bain Capital Life Sciences Investors opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 22,583,268 shares worth $498M. The stake represents 29.58% of the portfolio and ranks #1 among its holdings.

100 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

Bain Capital Life Sciences Investors held 22,583,268 shares of Kailera Therapeutics worth $498M as of Q2 2026.
Kailera Therapeutics was a new Bain Capital Life Sciences Investors position in Q2 2026.
Kailera Therapeutics made up 29.58% of Bain Capital Life Sciences Investors's portfolio in Q2 2026, its #1 holding.
100 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2026, filed 14 Aug 2026.